These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1989248)

  • 1. Combination immunosuppression with azathioprine reduces the incidence of ductopenic rejection and vanishing bile duct syndrome after liver transplantation.
    van Hoek B; Wiesner RH; Ludwig J; Gores GJ; Moore B; Krom RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1403-5. PubMed ID: 1989248
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome.
    van Hoek B; Wiesner RH; Ludwig J; Paya C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1442-3. PubMed ID: 1703343
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe ductopenic rejection with features of vanishing bile duct syndrome: clinical, biochemical, and histologic evidence for spontaneous resolution.
    Noack KB; Wiesner RH; Batts K; van Hoek B; Ludwig J
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1448-51. PubMed ID: 1989260
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible vanishing bile duct syndrome after liver transplantation: report of 6 cases.
    Hubscher SG; Buckels JA; Elias E; McMaster P; Neuberger JM
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1415-6. PubMed ID: 1989250
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe ductopenic rejection following liver transplantation: incidence, time of onset, risk factors, treatment, and outcome.
    van Hoek B; Wiesner RH; Krom RA; Ludwig J; Moore SB
    Semin Liver Dis; 1992 Feb; 12(1):41-50. PubMed ID: 1570550
    [No Abstract]   [Full Text] [Related]  

  • 6. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
    Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
    Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
    [No Abstract]   [Full Text] [Related]  

  • 7. [Value of a powerful initial immunosuppression after liver transplantation. Prospective study of 60 cases].
    Cherqui D; Duvoux C; Charlotte F; Humeres R; Lauzet JY; Métreau JM; Salvat A; Rotman N; Julien M; Fagniez PL
    Gastroenterol Clin Biol; 1994; 18(2):115-22. PubMed ID: 8013792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vanishing bile duct syndrome].
    Hashimoto E; Hayashi N
    Ryoikibetsu Shokogun Shirizu; 1995; (7):574-6. PubMed ID: 8749558
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts.
    Martelius T; Krogerus L; Höckerstedt K; Bruggeman C; Lautenschlager I
    Hepatology; 1998 Apr; 27(4):996-1002. PubMed ID: 9537439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
    Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
    [No Abstract]   [Full Text] [Related]  

  • 11. CsA levels in the early posttransplant period--predictive of chronic rejection in liver transplantation?
    Soin AS; Rasmussen A; Jamieson NV; Watson CJ; Friend PJ; Wight DG; Calne RY
    Transplantation; 1995 Apr; 59(8):1119-23. PubMed ID: 7732557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is exfoliative bile cytology useful in the diagnosis of graft complications in liver transplantation?
    Carrasco L; Sánchez-Bueno F; Sola J; Acosta F; Ramirez P; Robles R; Flores B; Parrilla P
    Transplant Proc; 1995 Aug; 27(4):2281-2. PubMed ID: 7652806
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of triple therapy and percutaneous needle biopsy to minimize graft failure following liver transplantation.
    St Cyr JA; Elick B; Freese D; Sharp H; Payne W; Bloomer J; Stock P; Snover D; Najarian JS; Ascher NL
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2451-3. PubMed ID: 3274535
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "the dualistic effect".
    Donaldson P; Underhill J; Doherty D; Hayllar K; Calne R; Tan KC; O'Grady J; Wight D; Portmann B; Williams R
    Hepatology; 1993 Jun; 17(6):1008-15. PubMed ID: 8514248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation.
    Ludwig J; Wiesner RH; Batts KP; Perkins JD; Krom RA
    Hepatology; 1987; 7(3):476-83. PubMed ID: 3552923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
    Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
    Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H
    Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
    [No Abstract]   [Full Text] [Related]  

  • 18. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients.
    McDiarmid SV; Millis M; Terashita G; Ament ME; Busuttil R; Terasaki P
    Transplant Proc; 1990 Aug; 22(4):1774-6. PubMed ID: 2117806
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimal clinical regimens for living related liver transplantation.
    Malagó M; Rogiers X; Wadström J; Burdelski M; Broelsch CE
    Transplant Proc; 1994 Oct; 26(5):2665-8. PubMed ID: 7940834
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of OKT3 in kidney, pancreas, and liver transplantation.
    D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
    Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.